NAD+ for Arthritis: What the Human Evidence Actually Tests

NAD+ injections and IV drips are not established arthritis treatments. Some vitamin B3 claims draw on a small oral niacinamide osteoarthritis trial. Its results cannot be treated as an NAD+ injection result ¹.

That distinction matters before paying for a joint-health program. Our NAD+, NMN and NR comparison explains why related compounds are not interchangeable. The NAD+ therapy evidence guide separates changes in a laboratory marker from improvements patients can feel or use.

Featured partner

CoreAge Rx

From $93/mo

Check availabilityRead our review

Affiliate link. We may earn a commission at no extra cost to you.

Affiliate partner

MadeMed

NAD+ injection & nasal spray, in 23 states

See MadeMed↗

Which kind of arthritis is the question about?

Arthritis is an umbrella term. Osteoarthritis involves changes in the tissues of a joint; rheumatoid arthritis is an autoimmune disease in which the immune system attacks healthy joint tissues. NIAMS emphasizes diagnosing the type so that treatment fits the condition ².

A result in osteoarthritis cannot establish benefit in rheumatoid arthritis. Nor can a laboratory finding about inflammation establish that an intervention prevents joint damage. When a product is described only as helping “arthritis” or “inflammation,” the missing diagnosis is a major gap in the claim.

For someone comparing treatments, the practical question is precise: does this particular product, by this route, improve pain, physical function or disease activity in people with the same diagnosis? Our NAD+ injection evidence review is useful background when a clinic cites oral precursor research to support a shot.

What the niacinamide trial found

Jonas and colleagues randomized 72 people with osteoarthritis to niacinamide or identical placebo for 12 weeks. Their assessment included overall arthritis impact, pain, movement and laboratory measures ¹.

Overall arthritis impact improved by 29% in the niacinamide group and worsened by 10% with placebo. Joint mobility also improved, and participants receiving niacinamide reduced anti-inflammatory medication use. However, the abstract explicitly reports that pain levels did not change. Side effects were described as mild but were more common with niacinamide ¹.

This is a signal worth describing accurately. It is not evidence that a vitamin eliminated arthritis pain, regrew cartilage or cured joint disease. The authors called for further evaluation. A short pilot also leaves long-term effectiveness and safety unresolved ¹.

Why that trial does not validate an NAD+ drip

Niacinamide, also called nicotinamide, is the substance named in that trial. Calling it “NAD-related” describes a biochemical relationship; it does not make its results a test of every product marketed to raise NAD+.

There are several separate leaps in an infusion claim: from niacinamide to NAD+, from an oral product to an intravenous one, and from selected short-term outcomes to lasting pain relief or joint protection. A citation to the original trial cannot resolve those differences. Ask for a study of the intervention actually being offered, rather than accepting a list of papers about related molecules.

This guide does not supply an arthritis dose for NAD+, NR or NMN. An amount used in a pilot involving another substance cannot define a proven regimen for these products. The NR versus other vitamin B3 forms guide explains another common naming confusion.

What rheumatoid arthritis research shows

A 2023 study examined NAD metabolism in people with RA and tested precursors on patient-derived immune cells in the laboratory. NR and nicotinamide increased cellular NAD+ and reduced several inflammatory features. The patients' improvement during anti-TNF treatment was a separate observation; they were not receiving an NR or NAD+ treatment in a clinical efficacy trial ⁵.

This is human-derived biological evidence, with an important boundary: treating extracted cells cannot establish pain relief or disease modification in the person from whom they came.

The 2026 NAD+ IV case report

A September 2026 report describes a woman diagnosed with RA who reported symptom improvement after NAD+ infusions. Follow-up ultrasound showed no previously documented synovitis or Doppler hyperemia. This is a real clinical observation, rather than a controlled trial ⁶.

The authors identify substantial limits: incomplete original diagnostic records, prior methotrexate exposure, concurrent psychological support, exercise and changed personal circumstances. Disease fluctuation and other explanations could account for improvement. The ultrasound comparisons were not standardized or blinded, and validated serial disease-activity measures were unavailable ⁶.

A case report can suggest what to test next. It cannot determine whether NAD+ caused recovery, how often patients benefit or whether a commercial course is safe and effective. The authors call for controlled prospective investigation ⁶.

Keep disease-modifying care in place

NIAMS notes that rheumatoid arthritis can cause damage early and that prompt treatment matters. Disease-modifying antirheumatic drugs, including biologic medicines and other options selected by the treating team, aim to limit disease activity and damage ³. Feeling temporarily more energetic after an optional treatment would not demonstrate that those goals have been achieved.

Do not use a supplement purchase as a reason to postpone assessment of persistent joint swelling or to change a prescribed arthritis medicine. Ask the rheumatology team to distinguish symptom control from prevention of damage.

Make the treatment comparison useful

For osteoarthritis, NIAMS describes individualized care that may include exercise, weight management when appropriate, physical support, medicines and sometimes surgery ⁴. The relevant comparison is what an additional intervention contributes to that plan.

Before considering an NAD-related product, identify one concrete goal: walking farther, less pain during daily activities, or improved hand function, for example. Ask the clinician how that outcome will be measured and whether the proposed product has been studied for it. Keep a complete list of ingredients and medicines available for review; our NMN interaction guide explains why incomplete combination data do not establish safety.

The useful conclusion is specific: the osteoarthritis pilot, RA cell experiments and one IV case report ask different questions. Together they support further research, without establishing NAD+ shots or infusions as arthritis treatment.